Asset profile
Trigel
Small molecule
Evidence outlook · lead readout
NCT02448914 · Parkinson's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT02448914: This trial had randomized treatment order and an active comparator, and it reached a statistically significant result for its primary measure, but it was not blinded, enrolled only 11 patients, and measured drug blood levels rather than a clinical symptom or functional outcome, so it demonstrates pharmacokinetic exposure rather than a proven clinical benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.